The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
UK: 11 November 2025: Patients in the UK will be able to access cutting-edge testing for Chronic Obstructive Pulmonary Disease (COPD) - the UK’s sixth biggest killer - as the NHS rolls out faster, ...
Clinical guidelines recommend long-acting bronchodilators as first maintenance therapy for chronic obstructive pulmonary disease (COPD), with inhaled corticosteroids (ICS) reserved for patients with ...
Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...
This article is developed and funded by Chiesi Ltd. Dr Sooj has been paid an honorarium for his author contribution. I’M Dr Suraj Kukadia, known as Dr Sooj, an NHS GP who has seen how life-changing ...
Doing targeted COPD case finding as part of NHS lung cancer checks could save £33m over the next decade, research has shown. The figures are based on a pilot project in Hull which found almost half of ...
UK ex-servicewomen are significantly more likely to experience health conditions such as COPD, osteoarthritis and obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback